Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study
Objectives The aims of our study were to examine the anticholinergic drug use and to assess the association between anticholinergic burden and cognitive function in the multimorbid elderly patients of the MultiCare cohort.Setting MultiCare was conducted as a longitudinal cohort study in primary care...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-03-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/11/3/e044230.full |
id |
doaj-24140e7a71634f70b74a4ba130e48acb |
---|---|
record_format |
Article |
spelling |
doaj-24140e7a71634f70b74a4ba130e48acb2021-07-02T13:08:32ZengBMJ Publishing GroupBMJ Open2044-60552021-03-0111310.1136/bmjopen-2020-044230Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational studyClaudia Langebrake0Gerhard Schön1Ingmar Schäfer2Wolfgang von Renteln-Kruse3Birgitt Wiese4Jochen Gensichen5Caroline Krüger6Hendrik van den Bussche7Horst Bickel8Angela Fuchs9Wolfgang Maier10Karola Mergenthal11Siegfried Weyerer12Department of Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Research, Albertinen-Haus Zentrum fur Geriatrie und Gerontologie Medizinisch-Geriatrische Klinik, Hamburg, GermanyInstitute for General Practice, Hannover Medical School, Hannover, GermanyInstitute of General Practice and Family Medicine, Ludwig-Maximilians-Universitat Munich, Munich, GermanyDepartment of Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Psychiatry, Technical University of Munich, Munich, GermanyInstitute of General Practice, Heinrich Heine University Düsseldorf, Dusseldorf, GermanyDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, GermanyInstitute of General Practice, Goethe University Frankfurt, Frankfurt am Main, GermanyDepartment of Medical Faculty Mannheim/Heidelberg, Central Institute of Mental Health, Mannheim, GermanyObjectives The aims of our study were to examine the anticholinergic drug use and to assess the association between anticholinergic burden and cognitive function in the multimorbid elderly patients of the MultiCare cohort.Setting MultiCare was conducted as a longitudinal cohort study in primary care, located in eight different study centres in Germany.Participants 3189 patients (59.3% female).Primary and secondary outcome measures Baseline data were used for the following analyses. Drugs were classified according to the well-established anticholinergic drug scale (ADS) and the recently published German anticholinergic burden (German ACB). Cognitive function was measured using a letter digit substitution test (LDST) and a mixed-effect multivariate linear regression was performed to calculate the influence of anticholinergic burden on the cognitive function.Results Patients used 1764 anticholinergic drugs according to ADS and 2750 anticholinergics according to the German ACB score (prevalence 38.4% and 53.7%, respectively). The mean ADS score was 0.8 (±1.3), and the mean German ACB score was 1.2 (±1.6) per patient. The most common ADS anticholinergic was furosemide (5.8%) and the most common ACB anticholinergic was metformin (13.7%). The majority of the identified anticholinergics were drugs with low anticholinergic potential: 80.2% (ADS) and 73.4% (ACB), respectively. An increasing ADS and German ACB score was associated with reduced cognitive function according to the LDST (−0.26; p=0.008 and −0.24; p=0.003, respectively).Conclusion Multimorbid elderly patients are in a high risk for using anticholinergic drugs according to ADS and German ACB score. We especially need to gain greater awareness for the contribution of drugs with low anticholinergic potential from the cardiovascular system. As anticholinergic drug use is associated with reduced cognitive function in multimorbid elderly patients, the importance of rational prescribing and also deprescribing needs to be further evaluated.Trial registration number ISRCTN89818205.https://bmjopen.bmj.com/content/11/3/e044230.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudia Langebrake Gerhard Schön Ingmar Schäfer Wolfgang von Renteln-Kruse Birgitt Wiese Jochen Gensichen Caroline Krüger Hendrik van den Bussche Horst Bickel Angela Fuchs Wolfgang Maier Karola Mergenthal Siegfried Weyerer |
spellingShingle |
Claudia Langebrake Gerhard Schön Ingmar Schäfer Wolfgang von Renteln-Kruse Birgitt Wiese Jochen Gensichen Caroline Krüger Hendrik van den Bussche Horst Bickel Angela Fuchs Wolfgang Maier Karola Mergenthal Siegfried Weyerer Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study BMJ Open |
author_facet |
Claudia Langebrake Gerhard Schön Ingmar Schäfer Wolfgang von Renteln-Kruse Birgitt Wiese Jochen Gensichen Caroline Krüger Hendrik van den Bussche Horst Bickel Angela Fuchs Wolfgang Maier Karola Mergenthal Siegfried Weyerer |
author_sort |
Claudia Langebrake |
title |
Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study |
title_short |
Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study |
title_full |
Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study |
title_fullStr |
Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study |
title_full_unstemmed |
Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study |
title_sort |
anticholinergic drug burden according to the anticholinergic drug scale and the german anticholinergic burden and their impact on cognitive function in multimorbid elderly german people: a multicentre observational study |
publisher |
BMJ Publishing Group |
series |
BMJ Open |
issn |
2044-6055 |
publishDate |
2021-03-01 |
description |
Objectives The aims of our study were to examine the anticholinergic drug use and to assess the association between anticholinergic burden and cognitive function in the multimorbid elderly patients of the MultiCare cohort.Setting MultiCare was conducted as a longitudinal cohort study in primary care, located in eight different study centres in Germany.Participants 3189 patients (59.3% female).Primary and secondary outcome measures Baseline data were used for the following analyses. Drugs were classified according to the well-established anticholinergic drug scale (ADS) and the recently published German anticholinergic burden (German ACB). Cognitive function was measured using a letter digit substitution test (LDST) and a mixed-effect multivariate linear regression was performed to calculate the influence of anticholinergic burden on the cognitive function.Results Patients used 1764 anticholinergic drugs according to ADS and 2750 anticholinergics according to the German ACB score (prevalence 38.4% and 53.7%, respectively). The mean ADS score was 0.8 (±1.3), and the mean German ACB score was 1.2 (±1.6) per patient. The most common ADS anticholinergic was furosemide (5.8%) and the most common ACB anticholinergic was metformin (13.7%). The majority of the identified anticholinergics were drugs with low anticholinergic potential: 80.2% (ADS) and 73.4% (ACB), respectively. An increasing ADS and German ACB score was associated with reduced cognitive function according to the LDST (−0.26; p=0.008 and −0.24; p=0.003, respectively).Conclusion Multimorbid elderly patients are in a high risk for using anticholinergic drugs according to ADS and German ACB score. We especially need to gain greater awareness for the contribution of drugs with low anticholinergic potential from the cardiovascular system. As anticholinergic drug use is associated with reduced cognitive function in multimorbid elderly patients, the importance of rational prescribing and also deprescribing needs to be further evaluated.Trial registration number ISRCTN89818205. |
url |
https://bmjopen.bmj.com/content/11/3/e044230.full |
work_keys_str_mv |
AT claudialangebrake anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT gerhardschon anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT ingmarschafer anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT wolfgangvonrentelnkruse anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT birgittwiese anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT jochengensichen anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT carolinekruger anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT hendrikvandenbussche anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT horstbickel anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT angelafuchs anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT wolfgangmaier anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT karolamergenthal anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy AT siegfriedweyerer anticholinergicdrugburdenaccordingtotheanticholinergicdrugscaleandthegermananticholinergicburdenandtheirimpactoncognitivefunctioninmultimorbidelderlygermanpeopleamulticentreobservationalstudy |
_version_ |
1721329190622461952 |